Membership

May 2014 Newsletter

May 2014 Newsletter - e-Cigarettes and Tobacco Cessation

 

Table of Contents

  President Corner

Tony Mok Photo

Tony S.K. Mok, IASLC President

The war on lung cancer started quietly in 1492 without a single soul on earth to realize its occurrence. Out of curiosity Lieutenant Rodrigo de Xeres, of the Columbus’ expedition, joined the local natives in smoking a native plant. As a result of this experience, tobacco was imported for the first time to Europe and subsequently became a luxury item for the European elite. Only a few decades later, tobacco smoking became a global epidemic leading to a rapid rise in the incidence of lung cancer. However, the understanding of this rise was retrospective. When Doll et al first reported the high rate of lung cancer death among British doctors in 1955, the lung cancer epidemic was already deeply rooted. Even when the scientific community rang the alarm bell as hard as they could, the tobacco companies continued to promote this deadly addiction. It took huge political effort and many years of hard work before a decline in tobacco consumption was noted in developed countries.

The scientific community and tobacco control agencies are now confronted with another challenge with e-cigarettes. Similar to 1492, this war started quietly. Pretending to be a safe alternative to tradition cigarettes, tobacco companies used the name of science to promote another potentially deadly addiction. We have great urgency to produce sufficient scientific proof on its carcinogenic effect. It is not just a race but another war. 

    CEO

Fred Hirsch

Fred R. Hirsch, IASLC Chief Executive Officer

Dear Colleagues,

These days at the Annual ASCO Meeting, IASLC is launching the IASLC Multidisciplinary Textbook, which will be available for subscription at the IASLC Booth at ASCO, but also through the IASLC website. The book can be subscribed as soft-cover copy or digital format, and will include regular updates of the different chapters. IASLC wants to congratulate and thank the Chief Editor, Dr. Harvey Pass and the Co-Editors; Dr. Giorgio Scagliotti and Dr. David Ball for their diligent work, which has been performed within a short scheduled timeline. IASLC is proud of having this significant project completed, and we are confident that this book will be of significant importance for all levels of health care personal dealing with lung cancer patients.  A great thanks should also go to Mrs. Deb Whippen, which has with great effort coordinated this project and been the Editorial Manager.

This month we also distribute our new Membership Directory. The Membership Directory is available in PDF format through our website.

IASLC has made plans for a specific Small Cell Lung Cancer Workshop to be held in April 2015. With the increasing interest for research within this type of lung cancer, we have created this work shop in order to make "guidance” and coordination in our research specifically focused on this subtype.

The preparation for the 16th World Conference on Lung Cancer in Denver, Colorado 2015 is now ongoing, and the IASLC will encourage all the IASLC members to make appropriate planning for the WCLC in September 2015. Several new program tracks will be launched, such as special track for community practices as well as for nurses and patients advocates. It is a great pleasure for me to welcome you to Denver 2015.

 

ASCO 2014

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Science and Society."
ASCO’s Lung Cancer Track provides members of IASLC with key education and science over four days. Below we have highlighted some key sessions along with a links to help plan your ASCO 2014.

Highlights:

Friday May 30 1:00 PM - 3:15 PM - Celebrating the 50th Anniversary of the Surgeon General's Report on Tobacco: Renewing Our Commitment to Effective Cancer Treatment and Control
Friday May 30 4:30 PM - 5:45 PM - 50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer
Saturday May 31 8:OO AM – 9:30 AM -
Targeting EGFR: The Next 10 Years

Be sure to check out the Oral Abstract Sessions Monday June 2: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers starting at 9:30 AM and then Lung Cancer - Non-small Cell Metastatic starting at 3:00 PM.

NSCLC – Metastatic Session:

Abstract #8003 3:48 PM - 4:00 PM
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

 Abstract #8005  4:12 PM - 4:24 PM
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.

 Abstract #8007  5:24 PM - 5:36 PM
Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).

Abstract #8008  5:36 PM - 5:48 PM
A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

 

SCLC and Other Session:
Abstract #7504  11:21 AM - 11:33 AM

A randomized phase III study of cisplatin (CDDP), etoposide (ETOP) and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC): Japan Clinical Oncology Group study JCOG0605

Abstract #7507  11:57 AM - 12:09 PM
Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma.

 

Genomics-Oriented Sessions:

Saturday May 31 4:45 PM - 6:00 PM - Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations
Sunday, June 1 9:45 AM - 11:00 AM - How to Talk with Your Pathologist about Molecular Testing

Plan your ASCO 2014 meeting:

ASCO  2014 iPlanner 
Sessions at a glance (PDF)
View the ASCO 2014 Meeting Abstracts

 

Registration and housing now open for the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology

Registration and housing are now open for the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, taking place October 30-November 1 at the Chicago Marriott Downtown Magnificent Mile. This two-and-a-half day meeting brings together physician specialists and practicing clinicians to examine multidisciplinary approaches for the treatment of thoracic cancers. Co-sponsored by the American Society of Clinical Oncology (ASCO), ASTRO, the International Association for the Study of Lung Cancer (IASLC) and the University of Chicago, the meeting includes case-based presentations and discussions on future directions for cancer treatment. Register by July 22 to receive the low early-bird rates. View Details

Registration Now Open for Asia-Pacific Lung Cancer Conference

We are delighted to announce that registration is now open for the 2014 IASLC Asia Pacific Lung Cancer Conference (APLCC 2014) which will be held in Kuala Lumpur, Malaysia from 6 to 8 November 2014.  Register Online Now

WEBINAR: Biomarkers and Personalized Medicine for Patients with Lung Cancer - June 23, 2014 at 8 pm EDT

IASLC Grand Rounds (CME): A Monthly Series of Live Webinars. 6th Webinar: Biomarkers and Personalized Medicine for Patients with Lung Cancer (Keith Kerr, MD) June 23, 2014 at 8:00 PM EDT. View Details

All IASLC Meeting Information

To see the full schedule of IASLC Meetings, visit our event page.

 

Meet the Investigator - Spotlight on e-Cigarettes – Matthew Peters, MD

Physician
Concord Hospital
Dept of Thoracic Medicine  

Q1: Please share with our members, what should a clinician say to a lung cancer patient who inquires about the use of e-cigarettes for smoking cessation?  Are there benefits to the use of e-Cigarettes?

The intent to stop smoking is good. Congratulate the patient for that intent. Smoking makes some lung cancer treatments impossible or unnecessarily dangerous, impairs the responses to treatments including chemotherapy and RT and impairs quality of life. However, e-Cigarettes have not been demonstrated to be equivalent to other treatment options. E-Cigarettes contain uncertain ingredients that may even accelerate lung cancer. This is too big a risk to take when there are safer options

 Q2: Please share the cons of lung cancer patients using e-Cigarettes?  

  • If e-cigarette use is ineffective, the patient is forgoing an effective approach for a speculative endeavor.
  • Uncertain safety 

Q3: Please add any other comments or thoughts on the future of e-Cigarettes?
There are many unproven strategies advocated to advance the interests of people challenged by lung cancer. E-Cigarettes joins a long list. E-cigarettes should be subject to FDA review as a drug – for efficacy and safety. Bodies in other jurisdictions should be the same. Whether containing nicotine or not, if it looks like a cigarettes and delivers chemical contents by inhalation into the lungs it should be regulated in this way. The fact that cigarettes are not is a regrettable, historical anomaly without which we would have a fraction of the lung cancer we see now.

 
e-Cigarettes and Tobacco Cessation - K. Michael Cummings, PhD, MHP

Professor
The Medical University of South Carolina
Specialty: Tobacco Control Policy
Tobacco Control and Smoking Cessation Committee Chair

Electronic cigarettes (i.e., e-cigarettes) are battery-powered devices that delivery nicotine in an aerosol to the user.  In contrast to nicotine gum and patches, interest in using e-cigarettes as an alternative to smoking seems to gaining traction in many countries.   Unlike medicinal nicotine products, e-cigarettes are being promoted as substitutes for conventional cigarettes, with explicit marketing strategies that emphasize reduced harm, and intended use to circumvent indoor smoking restrictions.   Also, the fact that e-cigarettes are engineered to look like cigarettes probably contributes to their appeal since the sensorimotor experiences tend to more closely approximate the act of cigarette smoking. 

However, there are many unanswered questions that arise about promoting a nicotine containing product, like an e-cigarette. While e-cigarettes are almost certainly safer than smoking conventional cigarettes, there is concern than nonsmokers might be attracted to try them, especially children.  Evidence from several studies in the United States shows increasing awareness and use of e-cigarettes by teenagers and young adults, although most regular user of e-cigarettes are limited to those already smoking cigarettes.  Among current smokers there is concern that e-cigarettes may delay quitting by giving people a false hope that they can mitigate their risk from smoking by occasionally substituting e-cigarettes for cigarettes.  However, data indicate that over 70% of adult smokers who report having used an e-cigarettes have done so in an effort to try to stop smoking regular cigarettes.  While data are limited, in one clinical trial evaluating e-cigarettes as a stop smoking method, fewer than 30% of those who had quit smoking were still using an e-cigarettes a year later. 

 

nEWS

Additional Prognostic Variables Identified in Pleural Mesothelioma

Refined models have been developed to better predict outcomes for patients with malignant pleural mesothelioma who are candidates for cytoreductive surgery. These prognostic models may provide a more accurate and minimally invasive method for predicting outcomes for patients who are surgical candidates, as well as determine patients who may benefit from chemotherapy. Read More

Subgroup of Patients with Small Cell Lung Cancer Defined

DENVER – The definition of distinct subgroups has not been as successful in small cell lung cancer (SCLC) as it has been in non-small cell lung cancer (NSCLC). Investigators have now described the clinical, pathologic, and molecular characteristics in a subgroup of SCLCs in never-smoking patients. Read More

 

textbook cover
Buy the IASLC Textbook

The IASLC Multidisciplinary Approach to Thoracic Oncology, is available for purchase, is designed to be the authoritative educational resource in the complex field of thoracic oncology. Purchase the textbook in soft-cover format for $225 $175 (plus shipping and handling), the digital book for $225 $175 or get both for $300 $250 (plus shipping and handling). Hurry for none members these great prices will only last until June 15th, 2014. When you purchase the digital copy you will recieve free undates through December 2016. Click Here to make your purchase.

 

Membership

IASLC Seachable 2014 Member Directory

The IASLC Searchable Online Member Directory is now available to all 2014 active members.  To access the directory, click the link below and login, using your IASLC username/email and password.  You can then search by name, location, and primary specialty.  If you have forgotten your IASLC password, please click the link below and use the "Forgot Password" option.

Login to Member Directory and JTO Access

IASLC 2013-2014 Printable Member Directory (PDF Version)

All 2014 members have been sent the private link to the 2014 Member Directory in your dues renewal confirmation email.   If you cannot locate this, please email membership@iaslc.org to request it. IASLC has designed this member directory to facilitate global cooperation and consultation among members. If you do not find the information you need, or if you need more detailed information for a specific project, please contact IASLC Membership staff at membership@iaslc.org or +1.720.325.2956.

Invite a Fellow for FREE IASLC Membership

You may already be aware that the IASLC offers FREE membership to fellows, but we want to make sure that more trainees around the world in multiple specialties are taking advantage of membership. Because of the importance of young investigators to the future of lung cancer research, fellows, residents and trainees may apply for free, non-voting membership by submitting a signed letter stating the term dates of their fellowship, residency or proof of trainee status from their department. 

Fellows, residents and trainees from all specialties are encouraged to join, including those from nursing and other allied health professions. Fellow membership is available for a maximum of two years. Fellows are non-voting members, entitled to many other IASLC benefits including online access to the Journal of Thoracic Oncology (JTO). 

Please invite a Fellow, Resident or Trainee today!

Member News

IASLC MEMBERS: If you have a newsworthy item or career change you would like featured, please email Rob Mansheim for consideration.

IASLC APLCC Committee Research Fellowship Award 1 year duration - Application Deadline August 15, 2014

The IASLC APLCC Committee is proud to announce the IASLC APLCC Research Fellowship  Award. It is one award for one year for an applicant from the Asia Pacific Area to be funded with $40,000 by an APLCC grant to work in US/EU major center in order to obtain laboratory skill and collaboration. Read More

IASLC MEMBERS: If you have a career or funding opportunity you would like featured in a future newsletter, please email Rob Mansheim for consideration.